MX369208B - Anticuerpo contra el receptor de tslp humana novedoso. - Google Patents
Anticuerpo contra el receptor de tslp humana novedoso.Info
- Publication number
- MX369208B MX369208B MX2016001796A MX2016001796A MX369208B MX 369208 B MX369208 B MX 369208B MX 2016001796 A MX2016001796 A MX 2016001796A MX 2016001796 A MX2016001796 A MX 2016001796A MX 369208 B MX369208 B MX 369208B
- Authority
- MX
- Mexico
- Prior art keywords
- human tslp
- tslp receptor
- receptor antibody
- amino acid
- human
- Prior art date
Links
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 title abstract 5
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 title abstract 5
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 abstract 2
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 241000244186 Ascaris Species 0.000 abstract 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 abstract 1
- 102100036845 C-C motif chemokine 22 Human genes 0.000 abstract 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 abstract 1
- 208000030961 allergic reaction Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000045535 human TSLP Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 230000008313 sensitization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un anticuerpo contra el receptor de TSLP humana para unirse específicamente al receptor de TSLP humana y bloquear el efecto de la TSLP humana mediada por el receptor de la TSLP humana. [Solución] Los inventores de la presente solicitud estudiaron el anticuerpo contra el receptor de la TSLP humana y han proporcionado un anticuerpo contra el receptor de la TSLP humana que incluye una región variable de cadena pesada compuesta de una secuencia de aminoácidos de los números de aminoácidos 1 a 110 del número de secuencia 1 y una región variable de cadena ligera compuesta de una secuencia de aminoácido de los números de aminoácidos 1 a 108 del número de secuencia. Los inventores de la presente perfeccionaron la invención al encontrar que el anticuerpo contra el receptor de la TSLP humana bloquea la expresión inducida por TSLP de ARNm de TARC y la producción de proteína MDC y que la reacción alérgica se inhibe en un modelo de sensibilización de antígeno de Ascaris de mono.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013165676 | 2013-08-09 | ||
| PCT/JP2014/071008 WO2015020193A1 (ja) | 2013-08-09 | 2014-08-08 | 新規抗ヒトｔｓｌｐ受容体抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016001796A MX2016001796A (es) | 2016-04-15 |
| MX369208B true MX369208B (es) | 2019-10-31 |
Family
ID=52461517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001796A MX369208B (es) | 2013-08-09 | 2014-08-08 | Anticuerpo contra el receptor de tslp humana novedoso. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9328171B2 (es) |
| EP (1) | EP3031913B1 (es) |
| JP (1) | JP6380394B2 (es) |
| KR (1) | KR102260680B1 (es) |
| AR (1) | AR097293A1 (es) |
| AU (1) | AU2014303356B2 (es) |
| BR (1) | BR112016002743B1 (es) |
| CA (1) | CA2920484C (es) |
| CY (1) | CY1121678T1 (es) |
| DK (1) | DK3031913T3 (es) |
| ES (1) | ES2730978T3 (es) |
| HK (1) | HK1223123A1 (es) |
| HR (1) | HRP20190752T1 (es) |
| HU (1) | HUE043111T2 (es) |
| IL (1) | IL243851B (es) |
| LT (1) | LT3031913T (es) |
| MX (1) | MX369208B (es) |
| MY (1) | MY177098A (es) |
| PH (1) | PH12016500237A1 (es) |
| PL (1) | PL3031913T3 (es) |
| PT (1) | PT3031913T (es) |
| RS (1) | RS58696B1 (es) |
| RU (1) | RU2689528C2 (es) |
| SG (1) | SG11201600935SA (es) |
| SI (1) | SI3031913T1 (es) |
| TR (1) | TR201906969T4 (es) |
| TW (1) | TWI635097B (es) |
| UA (1) | UA119328C2 (es) |
| WO (1) | WO2015020193A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017104778A1 (ja) * | 2015-12-18 | 2017-06-22 | アステラス製薬株式会社 | 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物 |
| IL299630A (en) | 2020-07-06 | 2023-03-01 | Flagship Pioneering Innovations Vi Llc | Antigen binding molecules targeting SARS Cov2 |
| KR20230058434A (ko) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
| CN114853888B (zh) * | 2021-02-05 | 2023-11-03 | 上海洛启生物医药技术有限公司 | 抗tslp纳米抗体及其应用 |
| CN113069543B (zh) * | 2021-06-07 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物 |
| WO2023028612A2 (en) * | 2021-08-27 | 2023-03-02 | Board Of Regents, The University Of Texas System | Anti-tslpr (crlf2) antibodies |
| CN114028562B (zh) * | 2021-11-01 | 2022-05-24 | 江苏荃信生物医药股份有限公司 | 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的液体制剂 |
| CN116217725B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的纯化方法 |
| CN117209603B (zh) * | 2021-12-02 | 2024-02-27 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
| US11993644B2 (en) | 2022-05-06 | 2024-05-28 | Generate Biomedicines, Inc. | Antigen binding molecules targeting SARS-CoV-2 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| US20240173405A1 (en) * | 2022-11-07 | 2024-05-30 | Upstream Bio, Inc. | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DK0690132T3 (da) | 1993-03-11 | 2004-04-13 | Chemo Sero Therapeut Res Inst | Monoklonalt anti-HIV-antistof |
| ES2391124T3 (es) * | 2000-06-28 | 2012-11-21 | Amgen Inc. | Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050249712A1 (en) * | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
| RU2486202C2 (ru) * | 2006-01-13 | 2013-06-27 | Айрм Ллк | Антитела к рецептору тимусного стромального лимфопоэтина |
| UA95329C2 (ru) * | 2006-12-14 | 2011-07-25 | Шеринг-Плау Лтд. | Собачий тимусный стромальный лимфопоэтин и его применение |
| AU2008265128A1 (en) | 2007-06-20 | 2008-12-24 | Irm Llc | Methods and compositions for treating allergic diseases |
| AR070346A1 (es) * | 2008-02-07 | 2010-03-31 | Schering Corp | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos |
| AR082163A1 (es) * | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| US20120020960A1 (en) * | 2010-07-26 | 2012-01-26 | Baylor Research Institute | Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer |
| EP2773774A4 (en) * | 2011-11-03 | 2015-06-10 | Merck Sharp & Dohme | BIOMARKERS FOR THE TREATMENT OF TSLP |
-
2014
- 2014-08-08 PT PT14833804T patent/PT3031913T/pt unknown
- 2014-08-08 MY MYPI2016700421A patent/MY177098A/en unknown
- 2014-08-08 HU HUE14833804A patent/HUE043111T2/hu unknown
- 2014-08-08 TW TW103127264A patent/TWI635097B/zh active
- 2014-08-08 JP JP2015530978A patent/JP6380394B2/ja active Active
- 2014-08-08 DK DK14833804.9T patent/DK3031913T3/da active
- 2014-08-08 EP EP14833804.9A patent/EP3031913B1/en active Active
- 2014-08-08 PL PL14833804T patent/PL3031913T3/pl unknown
- 2014-08-08 UA UAA201602101A patent/UA119328C2/uk unknown
- 2014-08-08 LT LTEP14833804.9T patent/LT3031913T/lt unknown
- 2014-08-08 BR BR112016002743-4A patent/BR112016002743B1/pt active IP Right Grant
- 2014-08-08 KR KR1020167005884A patent/KR102260680B1/ko active IP Right Grant
- 2014-08-08 RS RS20190580A patent/RS58696B1/sr unknown
- 2014-08-08 WO PCT/JP2014/071008 patent/WO2015020193A1/ja active Application Filing
- 2014-08-08 CA CA2920484A patent/CA2920484C/en active Active
- 2014-08-08 SG SG11201600935SA patent/SG11201600935SA/en unknown
- 2014-08-08 TR TR2019/06969T patent/TR201906969T4/tr unknown
- 2014-08-08 AR ARP140102993A patent/AR097293A1/es active IP Right Grant
- 2014-08-08 MX MX2016001796A patent/MX369208B/es active IP Right Grant
- 2014-08-08 AU AU2014303356A patent/AU2014303356B2/en active Active
- 2014-08-08 SI SI201431208T patent/SI3031913T1/sl unknown
- 2014-08-08 ES ES14833804T patent/ES2730978T3/es active Active
- 2014-08-08 RU RU2016107814A patent/RU2689528C2/ru active
-
2015
- 2015-10-29 US US14/927,007 patent/US9328171B2/en active Active
-
2016
- 2016-01-28 IL IL24385116A patent/IL243851B/en active IP Right Grant
- 2016-02-03 PH PH12016500237A patent/PH12016500237A1/en unknown
- 2016-04-04 US US15/090,051 patent/US9908941B2/en active Active
- 2016-09-23 HK HK16111216.7A patent/HK1223123A1/zh unknown
-
2019
- 2019-04-23 HR HRP20190752TT patent/HRP20190752T1/hr unknown
- 2019-05-08 CY CY20191100496T patent/CY1121678T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500237A1 (en) | Novel anti-human tslp receptor antibody | |
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| PH12020552080A1 (en) | Dll3-cd3 bispecific antibodies | |
| MX2019010172A (es) | Combinacion de un anticuerpo anti-cd16a con una citocina. | |
| MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
| MX2022011659A (es) | Proteinas de union a antigeno que se unen a pd-l1. | |
| JOP20190283B1 (ar) | طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها | |
| PH12015502293A1 (en) | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use | |
| EP4223874A3 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
| MY194328A (en) | Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| MX339239B (es) | Anticuerpos anti-cd40 y metodos de uso. | |
| MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| MY175878A (en) | Anti-il-17 antibodies, a method for producing and using thereof | |
| MX2022015258A (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. | |
| MX2015010428A (es) | Anticuerpos anti-her2 altamente galactosilados y sus usos. | |
| MX2015008534A (es) | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. | |
| CY1123519T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
| UA109148C2 (uk) | Композиції на основі антитіла проти vegfr-3 | |
| TN2013000068A1 (en) | Anti-vegfr-3 antibody compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |